ArticleScience translational medicine2011
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.
Article in Science translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.
- Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials.The Lancet. Microbe · 2025Pooled it
- Discovery of Quercetin as a Potential Entry Inhibitor of Nipah Virus: A Path Toward Antiviral Therapy.International journal of molecular sciences · 2026Article
- A single-cycle, recombinant VSV platform Nipah vaccine cross-protects against Hendra virus in nonhuman primates.PLoS pathogens · 2026Article
- Machine learning-driven drug repurposing and computational validation for Nipah virus.Molecular diversity · 2026Article
- Research hotspots and trend analyses of maximum biosafety level pathogens: A bibliometric study using China's 2023 catalogue of pathogens as an example.Biosafety and health · 2026Article
- The Nipah virus threat in India: Epidemiological trends, risk drivers, and lessons for pandemic preparedness.PLoS pathogens · 2026Review
- Three decades of discovery: An overview of Hendra virus, the original Henipavirus.PLoS neglected tropical diseases · 2026Review
- Protection against lethal canine distemper virus infection by a dual epitope-targeting synthetic antibody.Nature communications · 2026Article
- A single-cycle recombinant VSV vaccine displaying the Hendra virus glycoprotein uniformly protects against Hendra and Nipah virus challenge.NPJ vaccines · 2026Article
- Hendra virus: research progress on a bat-borne threat lurking at the human-animal interface.Frontiers in veterinary science · 2026Review
- Strengthening preparedness and response to emerging henipavirus diversity.Frontiers in cellular and infection microbiology · 2026Review
- A nanobody-based therapeutic targeting Nipah virus limits viral escape.Nature structural & molecular biology · 2025Article
- Nipah virus: a summary for clinicians.International journal of emergency medicine · 2025Review
- Potent Cross-neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nipah virus: pathogenesis, genome, diagnosis, and treatment.Applied microbiology and biotechnology · 2025Review
- Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics.Clinical microbiology reviews · 2025Review
- Establishing an immune correlate of protection for Nipah virus in nonhuman primates.NPJ vaccines · 2024Article
- A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease.Journal of virology · 2024Article
- Structure of the Nipah virus polymerase phosphoprotein complex.Nature communications · 2024Article
- Fully human single-domain antibody targeting a highly conserved cryptic epitope on the Nipah virus G protein.Nature communications · 2024Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
Abstract
Hendra virus (HeV) is a recently emerged zoonotic paramyxovirus that can cause a severe and often fatal disease in horses and humans. HeV is categorized as a biosafety level 4 agent, which has made the development of animal models and testing of potential therapeutics and vaccines challenging. Infection of African green monkeys (AGMs) with HeV was recently demonstrated, and disease mirrored fatal HeV infection in humans, manifesting as a multisystemic vasculitis with widespread virus replication in vascular tissues and severe pathologic manifestations in the lung, spleen, and brain. Here, we demonstrate that m102.4, a potent HeV-neutralizing human monoclonal antibody (hmAb), can protect AGMs from disease after infection with HeV. Fourteen AGMs were challenged intratracheally with a lethal dose of HeV, and 12 subjects were infused twice with a 100-mg dose of m102.4 beginning at either 10, 24, or 72 hours after infection and again about 48 hours later. The presence of viral RNA, infectious virus, and HeV-specific immune responses demonstrated that all subjects were infected after challenge. All 12 AGMs that received m102.4 survived infection, whereas the untreated control subjects succumbed to disease on day 8 after infection. Animals in the 72-hour treatment group exhibited neurological signs of disease, but all animals started to recover by day 16 after infection. These results represent successful post-exposure in vivo efficacy by an investigational drug against HeV and highlight the potential impact a hmAb can have on human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.